UZH2, established via optimization of UZH1a, was later confirmed to be another nanomolar inhibitor of METTL3 in AML cells and prostate cancer cells, showing better metabolic stability than UZH1a [144]. The gene discussed is METTL3; the disease is acute myeloid leukemia.